NeOnc Technologies Receives Written Feedback From FDA Regarding CMC Development Program For NEO212, Temozolomide-Perillyl Alcohol Conjugate; Co. Cancels July Meeting

Loading news article.

NeOnc Technologies Receives Written Feedback From FDA Regarding CMC Development Program For NEO212, Temozolomide-Perillyl Alcohol Conjugate; Co. Cancels July Meeting | WAPE

NeOnc Technologies Receives Written Feedback From FDA Regarding CMC Development Program For NEO212, Temozolomide-Perillyl Alcohol Conjugate; Co. Cancels July Meeting

Article summary

Related companies

Comments —